SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons quarterly results missed expectations and its full-year revenue outlook was cut, with delayed federal Dedrone deployments cited as a key timing factor, driving a sharp selloff. Traders are split between calling the drop an overreaction and buying the dip, and arguing that the weaker outlook makes the stocks still-high valuation harder to justify.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys three-year agreement to supply engines, license propulsion technology, and provide engineering support for AST SpaceMobiles planned rocketvalued at more than $1.3 billionis driving attention and a sharp share-price rally. Many traders view the deal as validation of Fireflys engine business and a boost to its backlog and funding outlook, while others question the payment mix, potential dilution, and execution risks ahead of earnings.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

A sharp pullback is dominating discussion, with traders largely attributing it to broader market and tech-sector weakness, while others point to oil and aviation-sector concerns. The community is divided between viewing the decline as a buying opportunity, citing Rolls-Royces buybacks and business backlog, and worrying about further weakness ahead of the upcoming trading update.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos selloff is being tied to analyst price-target cuts and concerns that networking-equipment growth may be peaking, weighing on valuation despite continued AI-infrastructure demand. Traders are split between calling the decline an overreaction and buying the dip, and arguing that weak momentum and growth concerns could keep pressure on the shares.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris strong Q3 results, driven by rapid Recorlev growth, and raised revenue outlook are fueling a sharp rerating, with traders also focused on the companys longer-term growth potential and planned XP-8121 Phase 3 trial. Takeover chatter is prominent, but speculation about a buyer or offer remains unconfirmed.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings steep selloff followed a weaker-than-expected Q3 report and a sharp reduction to its full-year outlook as the company ramps up spending on its Predictions business. Traders are split between viewing the investment as a costly gamble amid competition and regulatory uncertainty and seeing it as a growth opportunity, while many criticize managements execution.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms steep selloff and weak rebounds are drawing attention amid broader semiconductor weakness and concerns that AI data-center spending could slow, with traders also debating customer concentration and the risks of financing AI infrastructure deals. Bearish frustration over the stocks relative weakness contrasts with dip-buying optimism from investors who see the decline as an overreaction.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are using SCO as a leveraged bet on falling crude, focused on whether Iran-related de-escalation and restored shipping flows will ease oils supply-risk premium; others expect renewed conflict and higher crude to weigh on the fund. A major debate is whether SCOs daily reset and futures exposure erode returns or make it track oil poorly over longer holding periods.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs record quarterly results and raised full-year revenue outlook are driving attention, alongside reported growth from its SkyWater foundry acquisition. Traders welcomed the strong report and share rally, while some question how much growth is organic and remain wary of cash burn, dilution and execution risk.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientifics strong Q3 report has renewed attention on its shift from Bitcoin mining to AI data-center colocation, with traders highlighting rising capacity and the wind-down of mining operations. Reactions are divided: some see the pivot gaining traction, while others remain concerned about debt, execution, and reliance on major tenants amid weakness across AI infrastructure stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLCPR NewswireTORONTO, Nov. 3, 2026 TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL...

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx's Efficacy

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx's Efficacy Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of...

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsPR NewswireTORONTO, Sept. 16, 2026 Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in...

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by...

Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?

Here is how Aspen Pharmacare (APNHY) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire TORONTO, Sept. 9, 2026 TORONTO, Sept. 9, 2026...

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?

Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference PR Newswire TORONTO, Aug. 5, 2026 TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol...

This account has been verified as an official CRDL representative.

Verified Account

Cardiol Therapeutics Inc.

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc - Ordinary Shares - Class A

Extremely Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.995
Prev Close	$0.9265
Open	$0.9748
Dividend Yield	0.00%
50-Day Moving Average	$1.55
Beta	1.26
Avg. Volume	1.41M
PE Ratio	-3.74

52-Week High	$2.34
52-Week Low	$0.88
Market Capitalization	$111.79M
EPS (Annual)	-$0.2782
Price to Book	6.34
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRDL Fundamentals